Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adil I Daud

Showing results (31-40 of 85) with videos related to

Pageof 9
Sort By:
JCO Oncology Practice|July 1, 2020
Treatment of Metastatic Melanoma With Leptomeningeal Disease Using Intrathecal ImmunotherapyLaura A Huppert, Michelle E Melisko, Christine M Glastonbury, et al.
Molecular Cancer Therapeutics|December 24, 2005
In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlatesDouglas C Marchion, Elona Bicaku, Adil I Daud, et al.
Cancer Research|May 4, 2005
Valproic acid alters chromatin structure by regulation of chromatin modulation proteinsDouglas C Marchion, Elona Bicaku, Adil I Daud, et al.
Journal for Immunotherapy of Cancer|June 1, 2018
In-field and abscopal response after short-course radiation therapy in patients with metastatic Merkel cell carcinoma progressing on PD-1 checkpoint blockade: a case seriesMelody J Xu, Susan Wu, Adil I Daud, et al.
Journal of Computer Assisted Tomography|January 20, 2011
Tumor fistulization associated with targeted therapy: computed tomographic findings and clinical consequencesHenry Chow, Adam Jung, Jason Talbott, et al.
Cancer|September 19, 2008
State of the science 60th anniversary review: 60 Years of advances in cutaneous melanoma epidemiology, diagnosis, and treatment, as reported in the journal CancerMarie-France Demierre, Michael S Sabel, Kim A Margolin, et al.
Journal of Cellular Biochemistry|April 27, 2004
Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acidDouglas C Marchion, Elona Bicaku, Adil I Daud, et al.
Archives of Dermatology|May 18, 2011
NRAS-mutant melanoma: response to chemotherapyChristopher W M Soon, Alain P Algazi, Edward N Cha, et al.
Cancer Control : Journal of the Moffitt Cancer Center|July 4, 2008
Activated stat-3 in melanomaJane L Messina, Hua Yu, Adam I Riker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2005
Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbetaDouglas C Marchion, Elona Bicaku, Joel G Turner, et al.
Pageof 9

Showing results (31-40 of 85) with videos related to

Sort By:
Pageof 9
JCO Oncology Practice|July 1, 2020
Treatment of Metastatic Melanoma With Leptomeningeal Disease Using Intrathecal ImmunotherapyLaura A Huppert, Michelle E Melisko, Christine M Glastonbury, et al.
Molecular Cancer Therapeutics|December 24, 2005
In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlatesDouglas C Marchion, Elona Bicaku, Adil I Daud, et al.
Cancer Research|May 4, 2005
Valproic acid alters chromatin structure by regulation of chromatin modulation proteinsDouglas C Marchion, Elona Bicaku, Adil I Daud, et al.
Journal for Immunotherapy of Cancer|June 1, 2018
In-field and abscopal response after short-course radiation therapy in patients with metastatic Merkel cell carcinoma progressing on PD-1 checkpoint blockade: a case seriesMelody J Xu, Susan Wu, Adil I Daud, et al.
Journal of Computer Assisted Tomography|January 20, 2011
Tumor fistulization associated with targeted therapy: computed tomographic findings and clinical consequencesHenry Chow, Adam Jung, Jason Talbott, et al.
Cancer|September 19, 2008
State of the science 60th anniversary review: 60 Years of advances in cutaneous melanoma epidemiology, diagnosis, and treatment, as reported in the journal CancerMarie-France Demierre, Michael S Sabel, Kim A Margolin, et al.
Journal of Cellular Biochemistry|April 27, 2004
Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acidDouglas C Marchion, Elona Bicaku, Adil I Daud, et al.
Archives of Dermatology|May 18, 2011
NRAS-mutant melanoma: response to chemotherapyChristopher W M Soon, Alain P Algazi, Edward N Cha, et al.
Cancer Control : Journal of the Moffitt Cancer Center|July 4, 2008
Activated stat-3 in melanomaJane L Messina, Hua Yu, Adam I Riker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2005
Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbetaDouglas C Marchion, Elona Bicaku, Joel G Turner, et al.
Pageof 9